Merck gets another Phase 3 win for sac-TMT, this time in gastric cancer
An experimental antibody-drug conjugate from Merck has succeeded in another Phase 3 cancer study, potentially helping offset Keytruda's looming patent cliff. Merck said Friday morning that a pivotal trial testing sacituzumab ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.